Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Alkermes plc

Alkermes plc (ALKS) Stock Overview

Explore Alkermes plc’s financial performance, market position, analyst ratings, and future outlook.

ALKS●NASDAQ
HealthcareBiotechnology
$48.33
$0.31(0.65%)
U.S. Market opens in 55h 49m

Alkermes plc (ALKS)

Meyka AI Score

Z

Key Financials

Market Cap8.1B
P/E Ratio120.51
EPS (TTM)$0.95
ROE0.04%
Fundamental Analysis

AI Price Forecasts

1 Month$49.32
3 Months$65.23
1 Year Target$39.79

ALKS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Alkermes plc (NASDAQ: ALKS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Alkermes plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ALKS on the NASDAQ shows an RSI of 43.63, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $39.79 for the NASDAQ listing.

Key metrics behind Alkermes plc's NASDAQ-traded stock include a P/E ratio of 120.51 and a market capitalization of 8.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ALKS on the NASDAQ.

Price Performance (NASDAQ: ALKS)

1-Day Change
0.65%
5-Day Change
-2.11%
1-Month Change
-8.55%
3-Month Change
30.80%
6-Month Change
51.46%
Year-to-Date (YTD) Change
72.73%
1-Year Change
66.31%
3-Year Change
63.06%
5-Year Change
60.83%
All-Time (Max) Change
778.73%

Contact Information

http://www.alkermes.com
353 1 772 8000
Connaught House, Dublin, DU, D04 C5Y6

Company Facts

20,500 Employees
IPO DateJul 16, 1991
CountryIE
Actively Trading

Frequently Asked Questions